Who are Live attenuated SA 14-14-2 vaccine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Yellow fever vaccine, Institut Pasteur, Bacille Calmette-Guerin, BCG Solution, live attenuated Japanese encephalitis vaccine, Measles, mumps, rubella vaccine, Measles Vaccine (MV).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/live-attenuated-sa-14-14-2-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Live attenuated SA 14-14-2 vaccine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Live attenuated SA 14-14-2 vaccine (Live attenuated SA 14-14-2 vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live attenuated vaccine. Area: Immunology / Infectious Disease.

phase 3 Live attenuated vaccine Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Live attenuated SA 14-14-2 vaccine (Live attenuated SA 14-14-2 vaccine) — PATH. A live attenuated Japanese encephalitis virus vaccine that stimulates immune responses against Japanese encephalitis virus through controlled viral replication.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Live attenuated SA 14-14-2 vaccine TARGET	Live attenuated SA 14-14-2 vaccine	PATH	phase 3	Live attenuated vaccine
Yellow fever vaccine, Institut Pasteur	Yellow fever vaccine, Institut Pasteur	University of Oxford	marketed	Live attenuated vaccine
Bacille Calmette-Guerin	Bacille Calmette-Guerin	Urological Oncology Council of Northern Tokyo	marketed	Live attenuated vaccine / Immunotherapeutic agent
BCG Solution	BCG Solution	Alliance for Clinical Trials in Oncology	marketed	Live attenuated vaccine / Immunotherapy
live attenuated Japanese encephalitis vaccine	live attenuated Japanese encephalitis vaccine	Chinese Academy of Medical Sciences	marketed	Live attenuated vaccine
Measles, mumps, rubella vaccine	Measles, mumps, rubella vaccine	PATH	marketed	Live attenuated vaccine
Measles Vaccine (MV)	Measles Vaccine (MV)	PATH	marketed	Live attenuated vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live attenuated vaccine class)

GlaxoSmithKline · 19 drugs in this class
Merck Sharp & Dohme LLC · 11 drugs in this class
Sanofi Pasteur, a Sanofi Company · 9 drugs in this class
PATH · 5 drugs in this class
Sanofi · 5 drugs in this class
Bandim Health Project · 5 drugs in this class
Centers for Disease Control and Prevention · 3 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 3 drugs in this class
Beijing Center for Disease Control and Prevention · 2 drugs in this class
Aga Khan University · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Live attenuated SA 14-14-2 vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/live-attenuated-sa-14-14-2-vaccine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab